Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam effects on cardiac output during induction for coronary artery bypass grafting
ChiCTR2200056299Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, propofol and etomidate in coronary arteriosclerosis (3 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: cardiac output. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
remimazolampropofoletomidate
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200056299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056299.